FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1749229087> ?p ?o ?g. }

• W1749229087 endingPage "2606" @default.
• W1749229087 startingPage "2603" @default.
• W1749229087 abstract "To evaluate the efficacy and toxicity of gemcitabine, a novel pyrimidine antimetabolite with a low-toxicity profile and activity in several solid tumors, in patients with relapsed or refractory cutaneous T-cell lymphomas.Between May 1997 and February 1999, 44 previously treated patients with mycosis fungoides (MF; n = 30) and peripheral T-cell lymphoma unspecified (PTCLU) with exclusive skin involvement (n = 14) were enrolled onto a two-institution, phase II trial and treated with gemcitabine. This drug was given on days 1, 8, and 15 of a 28-day schedule at a dose of 1,200 mg/m(2) intravenously over 30 minutes for a total of three courses.Of the 44 patients, five (11. 5%) achieved complete responses (CRs), 26 (59%) partial responses (PRs), and the remaining 13 showed no benefit from the treatment. Two of the CRs were histologically confirmed. The CR and PR rates were the same for patients with MF and those with PTCLU, respectively. No difference in terms of overall response rate was observed between relapsed and refractory patients. The median durations of CR and PR were 15 months (range, 6 to 22 months) and 10 months (range, 2 to 15 months), respectively. Treatment was well tolerated; hematologic toxicity was mild, and no nausea/vomiting or organ toxicity was recorded.The results of the present phase II study show activity of gemcitabine as a single agent in patients with pretreated cutaneous T-cell lymphoma. Further studies that use gemcitabine alone or in combination with other drugs in earlier stages of the disease are needed." @default.
• W1749229087 created "2016-06-24" @default.
• W1749229087 creator A5001969767 @default.
• W1749229087 creator A5008693201 @default.
• W1749229087 creator A5009554954 @default.
• W1749229087 creator A5028241549 @default.
• W1749229087 creator A5029563827 @default.
• W1749229087 creator A5033359713 @default.
• W1749229087 creator A5043985252 @default.
• W1749229087 creator A5055651859 @default.
• W1749229087 creator A5058320427 @default.
• W1749229087 creator A5061078068 @default.
• W1749229087 creator A5065335175 @default.
• W1749229087 date "2000-07-01" @default.
• W1749229087 modified "2023-09-30" @default.
• W1749229087 title "Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients" @default.
• W1749229087 cites W1875404032 @default.
• W1749229087 cites W1890647543 @default.
• W1749229087 cites W1892026381 @default.
• W1749229087 cites W1895342060 @default.
• W1749229087 cites W1915689252 @default.
• W1749229087 cites W1970321630 @default.
• W1749229087 cites W1999995381 @default.
• W1749229087 cites W2013403355 @default.
• W1749229087 cites W2028950818 @default.
• W1749229087 cites W2097625513 @default.
• W1749229087 cites W2107202569 @default.
• W1749229087 cites W2124482385 @default.
• W1749229087 cites W2128997140 @default.
• W1749229087 cites W2241671946 @default.
• W1749229087 cites W2261126455 @default.
• W1749229087 cites W2300371971 @default.
• W1749229087 cites W2339293928 @default.
• W1749229087 cites W2341516404 @default.
• W1749229087 doi "https://doi.org/10.1200/jco.2000.18.13.2603" @default.
• W1749229087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10893292" @default.
• W1749229087 hasPublicationYear "2000" @default.
• W1749229087 type Work @default.
• W1749229087 sameAs 1749229087 @default.
• W1749229087 citedByCount "208" @default.
• W1749229087 countsByYear W17492290872012 @default.
• W1749229087 countsByYear W17492290872013 @default.
• W1749229087 countsByYear W17492290872014 @default.
• W1749229087 countsByYear W17492290872015 @default.
• W1749229087 countsByYear W17492290872016 @default.
• W1749229087 countsByYear W17492290872017 @default.
• W1749229087 countsByYear W17492290872018 @default.
• W1749229087 countsByYear W17492290872019 @default.
• W1749229087 countsByYear W17492290872020 @default.
• W1749229087 countsByYear W17492290872021 @default.
• W1749229087 countsByYear W17492290872022 @default.
• W1749229087 countsByYear W17492290872023 @default.
• W1749229087 crossrefType "journal-article" @default.
• W1749229087 hasAuthorship W1749229087A5001969767 @default.
• W1749229087 hasAuthorship W1749229087A5008693201 @default.
• W1749229087 hasAuthorship W1749229087A5009554954 @default.
• W1749229087 hasAuthorship W1749229087A5028241549 @default.
• W1749229087 hasAuthorship W1749229087A5029563827 @default.
• W1749229087 hasAuthorship W1749229087A5033359713 @default.
• W1749229087 hasAuthorship W1749229087A5043985252 @default.
• W1749229087 hasAuthorship W1749229087A5055651859 @default.
• W1749229087 hasAuthorship W1749229087A5058320427 @default.
• W1749229087 hasAuthorship W1749229087A5061078068 @default.
• W1749229087 hasAuthorship W1749229087A5065335175 @default.
• W1749229087 hasConcept C121332964 @default.
• W1749229087 hasConcept C126322002 @default.
• W1749229087 hasConcept C141071460 @default.
• W1749229087 hasConcept C142424586 @default.
• W1749229087 hasConcept C2776694085 @default.
• W1749229087 hasConcept C2776780870 @default.
• W1749229087 hasConcept C2777589544 @default.
• W1749229087 hasConcept C2777756187 @default.
• W1749229087 hasConcept C2778397455 @default.
• W1749229087 hasConcept C2779338263 @default.
• W1749229087 hasConcept C2780258809 @default.
• W1749229087 hasConcept C2780580376 @default.
• W1749229087 hasConcept C2780852908 @default.
• W1749229087 hasConcept C29730261 @default.
• W1749229087 hasConcept C31760486 @default.
• W1749229087 hasConcept C71924100 @default.
• W1749229087 hasConcept C87355193 @default.
• W1749229087 hasConcept C90924648 @default.
• W1749229087 hasConceptScore W1749229087C121332964 @default.
• W1749229087 hasConceptScore W1749229087C126322002 @default.
• W1749229087 hasConceptScore W1749229087C141071460 @default.
• W1749229087 hasConceptScore W1749229087C142424586 @default.
• W1749229087 hasConceptScore W1749229087C2776694085 @default.
• W1749229087 hasConceptScore W1749229087C2776780870 @default.
• W1749229087 hasConceptScore W1749229087C2777589544 @default.
• W1749229087 hasConceptScore W1749229087C2777756187 @default.
• W1749229087 hasConceptScore W1749229087C2778397455 @default.
• W1749229087 hasConceptScore W1749229087C2779338263 @default.
• W1749229087 hasConceptScore W1749229087C2780258809 @default.
• W1749229087 hasConceptScore W1749229087C2780580376 @default.
• W1749229087 hasConceptScore W1749229087C2780852908 @default.
• W1749229087 hasConceptScore W1749229087C29730261 @default.
• W1749229087 hasConceptScore W1749229087C31760486 @default.
• W1749229087 hasConceptScore W1749229087C71924100 @default.

• next